UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, with zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 | Regulation FD Disclosure. |
On March 24, 2022, Sientra, Inc. (the “Company”) issued a press release announcing a that it has received approval from Health Canada to market the Company’s line of smooth surface, High-Strength Cohesive (HSC and HSC+) silicone gel breast implants in Canada. A copy of the press release is furnished as Exhibit 99.1 hereto.
Item 8.01 | Other Events. |
On March 23, 2022, the Company received approval from Health Canada to market the Company’s line of smooth surface, High-Strength Cohesive (HSC and HSC+) silicone gel breast implants in Canada.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. |
Exhibit | |
99.1 | Press Release dated March 24, 2022 | |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
SIENTRA, INC. | ||||||
Date: March 24, 2022 | By: | /s/ Oliver Bennett | ||||
Oliver Bennett | ||||||
General Counsel and Vice President |
Exhibit 99.1
Sientra Receives Regulatory Approval to Market Breast Implants in Canada
Health Canada approval continues Sientras international expansion and growth acceleration
Santa Barbara, CA March 24, 2022 Sientra, Inc. (NASDAQ: SIEN) (Sientra or the Company), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced today that it has received approval from Health Canada to market the Companys line of smooth surface, High-Strength Cohesive (HSC and HSC+) silicone gel breast implants in Canada.
Ron Menezes, President and Chief Executive Officer of Sientra, said, Health Canadas approval of Sientra implants in Canada represents another significant milestone for the Company as we continue to strategically expand into international markets. As only the third silicone gel breast implant manufacturer approved in Canadaand the first in nearly two decadeswe look forward to providing Canadian consumers with the latest generation technology backed by our clinically-proven, unrivaled ten-year safety data,1 and our industry-leading Platinum20 warranty.
Sientra will market its breast implants in Canada through its local partner Kai Aesthetic, a leading distributor of medical aesthetics products and technology. In partnership with Kai, Sientra will uphold the highest product, safety and service standards to patients and board-certified plastic surgeons.
After watching its development for close to 20 years, the introduction of this new breast technology into the Canadian market is exciting for plastic surgeons and their patients, said Dr. Julie Khanna, plastic surgeon at ICLS in Oakville, Ontario, and past president of the Canadian Society of Plastic Surgeons. With Sientras compelling 10-year safety data and low product complication rates, this is going to be a huge benefit for our patients.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Companys mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The
1 | Stevens WG, Calobrace MB, Alizadeh K, Zeidler KR, Harrington JL, dIncelli RC. Ten-year core study data for Sientras food and drug administration-approved round and shaped breast implants with cohesive silicone gel. Plast Reconstr Surg. 2018;141:7S-19S. |
Companys product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).
Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Companys investor relations website at www.sientra.com.
For Canadian plastic surgeons and consumers seeking further information about Sientra silicone gel breast implants, including important safety information concerning breast implants, please visit www.sientra.ca.
(*) | Data on file |
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on managements current assumptions and expectations of future events and trends, which affect or may affect the Companys business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are made only as of the date of this release. The words believe, may, might, could, will, aim, estimate, continue, anticipate, intend, expect, plan, position, or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Forward-looking statements may include information concerning the Companys expansion into international markets, the Companys prospects and opportunities in Canada for its breast implants, and the adoption of the Companys products in Canada by plastic surgeons and consumers. Such statements are subject to risks and uncertainties, including the positive reaction from plastic surgeons and their patients the Companys products in Canada, the Companys ability to successfully leverage its commercial team and brand to generate significant breast implants sales in Canada, the Companys ability to execute on its commercial, clinical and research and development plans for international expansion. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientras public filings with the Securities and Exchange Commission. All statements other than statements of historical fact are forward-looking statements. The words believe, may, might, could, will, aim, estimate, continue, anticipate, intend, expect, plan, position, or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, and such estimates,
projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Companys business.
Contact
Leigh Salvo
ir@sientra.com
Document and Entity Information |
Mar. 23, 2022 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001551693 |
Document Type | 8-K |
Document Period End Date | Mar. 23, 2022 |
Entity Registrant Name | SIENTRA, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-36709 |
Entity Tax Identification Number | 20-5551000 |
Entity Address, Address Line One | 420 South Fairview Avenue |
Entity Address, Address Line Two | Suite 200 |
Entity Address, City or Town | Santa Barbara |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 93117 |
City Area Code | (805) |
Local Phone Number | 562-3500 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.01 per share |
Trading Symbol | SIEN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G
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